[Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
D002986:Clinical Trials as Topic; D003548:Cysteinyldopa / Q000652:urine*; D003606:Dacarbazine / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000652:urine; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000652:urine; D014226:Triazenes / Q000627:therapeutic use*
D014226:Triazenes; D003548:Cysteinyldopa; D004295:Dihydroxyphenylalanine; D003606:Dacarbazine
Behandling av maligna melanom med DTIC--terapieffekten ultäst av 5-S-cysteinyldopaförändringer i urinen.